Mundipharma and Cidara Present Results of Rezafungin in P-III (ReSTORE) Trial for Treatment of Candidemia or Invasive Candidiasis at ECCMID 2022
Shots:
- The P-III (ReSTORE) trial evaluates rezafungin (qw) vs caspofungin in a ratio (1:1) in 199 patients with candidemia & IC at 66 sites across 18 countries
- The trial met its 1EPs of non-inferiority. The results from P-III (ReSTORE) trial & integrated analysis of the P-II (STRIVE) & P-III (ReSTORE) showed (23.7% vs 21.3%) & (18.7% vs 19.4%) all-cause mortality on day 30, -ve blood culture @24hrs. (53.7% vs 46.2%) & (60.0% vs 49.1%) while (74.2% vs 64.1%) & (77.7% vs 63.5%) @48hrs., respectively
- The median time to -ve blood culture (23.9hrs vs 27hrs.) & (22.3hrs. vs 26.3hrs.). In (ReSTORE) trial, global cure on day 14 (59.1% vs 60.6%), high rates of mycological efficacy, similar tolerability with no trends in TEAEs or SAEs
Ref: Businesswire | Image: Mundipharma
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
